# Immune Response to COVID-19 Vaccine in Multiple Sclerosis Patients Treated With Teriflunomide and Alemtuzumab

> **NCT05075499** · NA · UNKNOWN · sponsor: **Sheba Medical Center** · enrollment: 70 (estimated)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **BIOLOGICAL:** COVID-19 vaccination

## Key facts

- **NCT ID:** NCT05075499
- **Lead sponsor:** Sheba Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-20
- **Primary completion:** 2021-12
- **Final completion:** 2022-09
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2021-10-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05075499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05075499, "Immune Response to COVID-19 Vaccine in Multiple Sclerosis Patients Treated With Teriflunomide and Alemtuzumab". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05075499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*